STUDY OBJECTIVES: To evaluate the safety and tolerability of infliximab in the treatment of active pulmonary sarcoidosis, and to provide an initial assessment of the efficacy of infliximab in the treatment of active pulmonary sarcoidosis. DESIGN: Double-blind, randomized, placebo-controlled phase II study. SETTING: Multicenter. PATIENTS: Active Radiographic Stage II, III, and IV active pulmonary sarcoidosis despite corticosteroids or previous intolerance to corticosteroids. INTERVENTION: Infliximab 5mg/kg (group I) or placebo (group II) at weeks 0 and 2 and open-label infliximab 5mg/kg for all subjects at weeks 6 and 14. MEASUREMENTS: Pulmonary function, chest radiographs, dyspnea stage, SF-36. RESULTS:Mean vital capacity (VC) at wk 0 was 2.47 +/- 0.2 (group I) and 2.37 +/- 0.31 (group II). At 6 weeks the mean +/- SD relative change in VC compared to baseline was 15.22 +/- 9.91% for group I (n=13) and 8.39 +/- 3.33% for group II (n=6) (p=0.65). Four patients had serious adverse events, including decreased WBC and elevated CPK (1 patient), pneumonia (1 patient), cellulitis, acute renal failure, pulmonary embolus and death (1 patient), and visual field defect (1 patient). CONCLUSIONS:Infliximab may improve VC in patients with active PS resistant to steroids. Larger scale, longer term studies will be needed to assess both safety and efficacy.
RCT Entities:
STUDY OBJECTIVES: To evaluate the safety and tolerability of infliximab in the treatment of active pulmonary sarcoidosis, and to provide an initial assessment of the efficacy of infliximab in the treatment of active pulmonary sarcoidosis. DESIGN: Double-blind, randomized, placebo-controlled phase II study. SETTING: Multicenter. PATIENTS: Active Radiographic Stage II, III, and IV active pulmonary sarcoidosis despite corticosteroids or previous intolerance to corticosteroids. INTERVENTION: Infliximab 5mg/kg (group I) or placebo (group II) at weeks 0 and 2 and open-label infliximab 5mg/kg for all subjects at weeks 6 and 14. MEASUREMENTS: Pulmonary function, chest radiographs, dyspnea stage, SF-36. RESULTS: Mean vital capacity (VC) at wk 0 was 2.47 +/- 0.2 (group I) and 2.37 +/- 0.31 (group II). At 6 weeks the mean +/- SD relative change in VC compared to baseline was 15.22 +/- 9.91% for group I (n=13) and 8.39 +/- 3.33% for group II (n=6) (p=0.65). Four patients had serious adverse events, including decreased WBC and elevated CPK (1 patient), pneumonia (1 patient), cellulitis, acute renal failure, pulmonary embolus and death (1 patient), and visual field defect (1 patient). CONCLUSIONS:Infliximab may improve VC in patients with active PS resistant to steroids. Larger scale, longer term studies will be needed to assess both safety and efficacy.
Authors: Cándido Díaz-Lagares; Roberto Pérez-Alvarez; Francisco J García-Hernández; María M Ayala-Gutiérrez; José Luis Callejas; Agustín Martínez-Berriotxoa; Javier Rascón; Luis Caminal-Montero; Albert Selva-O'Callaghan; Joaquim Oristrell; Carmen Hidalgo; Ricardo Gómez-de-la-Torre; Luis Sáez; Jesús Canora-Lebrato; María-Teresa Camps; Norberto Ortego-Centeno; María-Jesús Castillo-Palma; Manuel Ramos-Casals Journal: Arthritis Res Ther Date: 2011-07-11 Impact factor: 5.156